Clinical Trials /

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

NCT04209660

Description:

The purpose of this study is to see if the study drugs, lenvatinib and pembrolizumab, are effective in treating advanced Adenoid Cystic Carcinoma (ACC) or other salivary gland cancers that have come back and/or spread to other parts of the body. Researchers are also doing this study to test the safety of the study drugs in participants.

Related Conditions:
  • Adenoid Cystic Carcinoma
  • Salivary Gland Adenocarcinoma
Recruiting Status:

Not yet recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
  • Official Title: A Phase II Study of Lenvatinib Plus Pembrolizumab in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma and Other Salivary Gland Cancers

Clinical Trial IDs

  • ORG STUDY ID: 19-310
  • NCT ID: NCT04209660

Conditions

  • Adenoid Cystic Carcinoma
  • Salivary Gland Cancer

Interventions

DrugSynonymsArms
Lenvatinibrecurrent/metastatic adenoid cystic carcinoma (R/M ACC)
Pembrolizumabrecurrent/metastatic adenoid cystic carcinoma (R/M ACC)

Purpose

The purpose of this study is to see if the study drugs, lenvatinib and pembrolizumab, are effective in treating advanced Adenoid Cystic Carcinoma (ACC) or other salivary gland cancers that have come back and/or spread to other parts of the body. Researchers are also doing this study to test the safety of the study drugs in participants.

Trial Arms

NameTypeDescriptionInterventions
recurrent/metastatic adenoid cystic carcinoma (R/M ACC)ExperimentalAll eligible patients will undergo informed consent and screening for trial enrollment. Enrolled patients will receive a starting lenvatinib dose of 20mg daily taken orally and pembrolizumab 200mg intravenously every 3 weeks (1 cycle=3 weeks)
  • Lenvatinib
  • Pembrolizumab
recurrent/metastatic non-ACC salivary gland cancers (R/M SGC).ExperimentalAll eligible patients will undergo informed consent and screening for trial enrollment. Enrolled patients will receive a starting lenvatinib dose of 20mg daily taken orally and pembrolizumab 200mg intravenously every 3 weeks (1 cycle=3 weeks)
  • Lenvatinib
  • Pembrolizumab

Eligibility Criteria

        Inclusion Criteria:

          -  ACC Cohort (Cohort 1) only: Patients must have pathologically or cytologically
             confirmed adenoid cystic carcinoma. Cancers arising from non-salivary gland primary
             sites are allowed.

          -  Non-ACC Cohort (Cohort 2) only: Patients must have pathologically or cytologically
             confirmed salivary gland cancer of any histology (except for adenoid cystic carcinoma
             that is enrolled into cohort 1).

          -  Patients must have recurrent and/or metastatic disease not amenable to other curative
             intent therapy.

          -  At least 2 weeks must have elapsed since the end of prior systemic treatment and/or 4
             weeks since completion of radiotherapy with resolution of all treatment related
             toxicity to NCI CTCAE Version 5.0 grade ≤1 (or tolerable grade 2) or back to baseline
             (except for alopecia, lymphopenia, or hypothyroidism) prior to starting study drug
             treatment.

          -  Patients must have RECIST V1.1 measurable disease as defined as at least one lesion
             that can be accurately measured in at least one dimension (longest diameter to be
             recorded for non-nodal lesions and short axis for nodal lesions) as

             ≥ 20 mm with conventional techniques or as ≥10mm with CT scan, MRI, or calipers by
             clinical exam. Tumors in previously irradiated fields may be considered measurable if
             there is evidence of tumor progression after radiation treatment.

          -  Cohort 1 and acinic cell carcinoma patients in Cohort 2 only: Patients must have
             documentation of a new or progressive lesion on radiologic imaging study performed
             within 6 months prior to study enrollment (progression of disease over any interval is
             allowed) and/or new/worsening disease related symptoms within 6 months prior to study
             enrollment. Note: This assessment will be performed by the treating investigator and
             evidence of progression by RECIST criteria is not required.

          -  Age ≥ 18 years of age on the day of signing informed consent.

          -  ECOG performance status 0 or 1 (or Karnofsky ≥ 70%).

          -  Patients must have tissue from the primary tumor or metastases available for
             correlative studies. Either a paraffin block or at least 20 unstained slides are
             acceptable (paraffin block or at 30 unstained slides would be ideal).

          -  Screening laboratory values must meet the following criteria:

               -  Neutrophils ≥1500/μL

               -  Platelets ≥ 100x10^3/μL

               -  Hemoglobin ≥ 9.0 g/dL (without packed red blood cell (pRBC) transfusion within
                  the last 2 weeks)

               -  AST and ALT ≤ 2.5 x ULN (if liver metastases are present, AST and ALT ≤ 5x ULN)

               -  Total Bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ULN for participants with total
                  bilirubin levels >1.5 x ULN (except participants with Gilbert Syndrome, who can
                  have a total bilirubin < 3.0 mg/dL)

               -  Serum creatinine ≤ 1.5 x ULN OR creatinine clearance (CrCl) ≥ 40 mL/min per the
                  Cockcroft-Gault formula if creatinine is >1.5 x ULN

               -  Female CrCl = (140 - age in years) x weight in kg x 0.85 72 serum creatinine in
                  mg/dL

               -  Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in
                  mg/dL

               -  INR OR prothrombin time (PT) < 1.5, unless participant is receiving anticoagulant
                  therapy as long as PT or aPTT is within therapeutic range of intended use of
                  anticoagulants

          -  Participants must be willing to sign the written informed consent form. A signed
             informed consent form must be appropriately obtained prior to the conduct of any trial
             specific procedure.

          -  Male participants must agree to use adequate contraception as detailed in Appendix 2
             (complete abstinence, male condom) of this protocol during the treatment period and
             for at least 120 days after the last dose of study therapy and refrain from donating
             sperm during this period.

          -  A female participant is eligible to participate if she is not pregnant (for women of
             child-bearing potential, urine pregnancy test must be negative within 72 hours prior
             to initiation; if urine test is positive or cannot be confirmed as negative, a serum
             pregnancy test will be required), not breast feeding, and at least one of the
             following conditions applies:

               -  Not a woman of child bearing potential including:

               -  pre-menopausal with one of the following: documented hysterectomy, documented
                  bilateral salpingectomy, documented bilateral oophorectomy

               -  Postmenopausal females defined as no menses for 12 months without an alternative
                  medical cause (a high follicle stimulating hormone level in the postmenopausal
                  range may be used to confirm a post-menopausal state in women not using hormonal
                  contraception or hormonal replacement therapy (HRT). However, in the absence of
                  12 months of amenorrhea, confirmation with two FSH measurements in the
                  postmenopausal range is required.

               -  A woman of child bearing potential who agrees to highly effective contraception
                  from the start of therapy through 120 days after the last dose of study
                  medication

               -  Participants must be able to swallow and retain oral medication or have a
                  functioning G-tube in place.

        Exclusion Criteria:

          -  Untreated metastatic brain (subjects with treated brain metastases will be eligible,
             provided that they are radiographically stable, i.e. without evidence of progression
             for at least 4 weeks by repeat imaging (note that the repeat imaging should be
             performed during study screening), clinically stable and without requirement of
             steroid treatment for at least 14 days prior to the first dose of study treatment).

          -  Concurrent anti-cancer therapy (chemotherapy, definitive radiation therapy, surgery,
             immunotherapy, biologic therapy or tumor embolization) other than study treatment.
             Concurrent therapy with bisphosphonates or denosumab for bone metastases is allowed,
             provided they are started prior to study entry. Palliative radiation to non-target
             lesions is also allowed.

          -  Prior malignancy if diagnosed and treated within 2 years of trial drug initiation
             (with the exception of non-melanomatous skin cancers). Patients may be included if
             they have completed therapy for a prior malignancy >2 years prior to drug initiation
             and are currently NED. Participants with basal cell carcinoma of the skin, squamous
             cell carcinoma of the skin, or carcinoma in situ (breast DCIS, or cervical CIS) that
             have undergone potentially curative therapy are not excluded from trial participation.

          -  History of allergy or intolerance to study drug components (or any of their
             excipients), or severe (> Grade 3) hypersensitivity reaction to pembrolizumab and/or
             any of its excipients or any monoclonal antibody.

          -  Prior use of lenvatinib or any PD-1/PD-L1 or anti-PD-L2 targeted therapies or with an
             agent directed at another stimulatory or co-inhibitory T-cell receptor (CTLA-4, OX-40,
             CD137).

          -  Uncontrolled hypertension (systolic pressure >140mm Hg or diastolic pressure >90mm Hg,
             despite optimal medical management.

          -  Prior systemic anti-cancer therapy including use of another investigation drug or
             device (i.e., outside study treatment) during, or within 4 weeks of trial entry (time
             of initiation of experimental drug).

          -  Has received prior radiotherapy within 2 weeks fo the start of study treatment.
             Participants must have recovered from all radiation-related toxicities, not require
             corticosteroids, and not have had radiation pneumonitis.

          -  Participants must have recovered all AEs due to previous therapies to ≤ Grade 1 or
             baseline. Participants with ≤ Grade 2 neuropathy or alopecia may be eligible. If
             participant received major surgery, they must have recovered adequately from the
             toxicity and/or complications from the intervention prior to starting study treatment.

          -  Clinically significant proteinuria:

             °Subjects having >1+ proteinuria on urinalysis will undergo 24-hour urine collection
             for quantitative assessment of proteinuria. Subjects with proteinuria ≥1gm/24-hour
             will be ineligible.

          -  Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition
             that might affect the absorption of lenvatinib.

          -  New York Heart Association congestive heart failure of grade II or above, unstable
             angina, myocardial infarction within the past 6 months, or serious cardiac arrhythmia
             associated with significant cardiovascular impairment within the past 6 months
             (baseline echocardiogram is not required unless clinically indicated).

          -  Subjects with thrombotic, embolic, venous or arterial events, such as cerebrovascular
             accidents (including transient ischemic attacks), deep venous thrombosis or pulmonary
             embolism within 6 months of study treatment start.

          -  Therapeutic anticoagulation with Vitamin-K antagonists (e.g., warfarin) is not allowed
             if the medication dose and/or INR is not considered stable by the treating physician.
             If the dose and/or INR is stable, therapeutic anticoagulation with Vitamin-K
             antagonists is allowed with close monitoring. Anticoagulation with heparin or low
             molecular weight heparin is allowed.

          -  Prolongation of QTc interval to >480 msec

          -  Any hemorrhage or bleeding event ≥ NCI CTCAE v5.0 Grade ≥3 within 4 weeks prior to
             start of study medication.

          -  Active infection (any infection requiring systemic treatment)

          -  Subject is known to be positive for Human Immunodeficiency Virus (HIV) or active
             Hepatitis C Virus (HCV) or active hepatitis B (HBV) infection (positive viral load).
             Testing for HIV, HCV, or HBV prior to initiation of the study drug is not required. If
             patient's have a known history of treated HCV, then a viral load is required to
             confirm clearance of infection.

          -  Serious non-healing wound, ulcer or bone fracture, that is not tumor related.

          -  History of organ allograft (including corneal transplant).

          -  Biologic response modifiers (e.g., granulocyte colony-stimulating factor) within 4
             weeks before study entry. Chronic erythropoietin therapy is permitted provided that no
             dose adjustments were made within 2 months before first dose of study treatment.

          -  Has a history or current evidence of any medical or other condition, therapy or
             laboratory abnormality which, in the opinion of the investigator, might confound the
             results of the study, or preclude participation in a clinical study.

          -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any
             other form of immunosuppressive therapy within 7 days prior to the first dose of study
             treatment. The use of physiologic doses of corticosteroids (up to 10 mg/d of
             prednisone or equivalent) may be approved after consultation with the Primary
             Investigator.

          -  Active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e., with the use of disease modifying agents, corticosteroids or immunosuppressive
             drugs), with the exception of autoimmune thyroid disease, vitiligo, type 1 diabetes
             mellitus, or psoriasis. Replacement therapy (e.g., thyroxine, insulin, or physiologic
             corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is
             not considered a form of systemic treatment.

          -  Has a history of (non-infectious) pneumonitis that required steroids, or current
             pneumonitis.

          -  Renal failure requiring active hemo- or peritoneal dialysis.

          -  Has received a live-virus vaccination within 30 days of planned treatment start.
             Examples of live vaccines include, but are not limited to, the following: measles,
             mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
             Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection
             are generally killed virus vaccines and are allowed; however, intranasal influenza
             vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.

          -  Has known psychiatric or substance abuse disorders that would interfere with the
             cooperation with the requirements of the trial.

          -  Is pregnant or breast feeding, or expecting to conceive or father children within the
             projected duration of the study, starting with the screening visit through 120 days
             after the last dose of trial treatment.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:best overall response rate
Time Frame:2 years
Safety Issue:
Description:Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)

Secondary Outcome Measures

Measure:median progression-free survival (PFS)
Time Frame:2 years
Safety Issue:
Description:Response and progression will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:Memorial Sloan Kettering Cancer Center

Trial Keywords

  • Lenvatinib
  • Pembrolizumab
  • 19-310

Last Updated

December 20, 2019